Please login to the form below

Not currently logged in
Email:
Password:

Novartis COX2 taken off Australian market

The Therapeutic Goods Administration regulatory body of Australia rejects the registration of Novartis' COX2-inhibitor painkiller Prexige over liver-related toxicity

The Therapeutic Goods Administration regulatory body of Australia (TGA) has rejected the registration of Swiss-headquartered Novartis' COX2-inhibitor painkiller Prexige (lumiracoxib) over liver-related toxicity.

Up to the 10 August, the TGA had received eight reports of serious liver-related adverse reactions to the drug, including two deaths and two liver transplants, according to a press statement given by Dr Rohan Hammett, the TGA's principal medical adviser.

The safety concerns in Australia follow those in the US related to the now infamous COX2 drug, Vioxx (rofecoxib). US-based Merck & Co, which manufactured the drug, withdrew it from the global market in Q3 2004 after clinical studies demonstrated elevated risks of heart attacks and stroke.

In April 2005, Pfizer took its Bextra (valdecoxib) product over similar cardiac scares. Both firms are still involved in lawsuits from injured patients or families of those that died. Only Pfizer's Celebrex (celecoxib) remains on the US market.

Prexige was approved in Australia in July 2004, but had only recently become widely available since winning reimbursement status.

Novartis is collaborating with the Australian regulator, but said it believed that Prexige had a positive benefit/risk profile in the treatment of appropriate patients with osteoarthritis and acute pain.

In the US, the FDA will decide whether to approve Prexige in September 2007, but the majority of analysts doubt that the ruling will be positive.

Since Prexige won EU approval in 2006, the company has begun marketing it in the region. Approval for the drug is still pending in the Swiss market.

Since Prexige was launched, more than seven million prescriptions have been written globally, according to Novartis. The drug racked up worldwide sales of USD 52m in H1 FY07. Shares in the company closed at CHF 64.95 (USD 53.71) on 10 August and so far in 2007 the stock value has dropped over six per cent.

14th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....